Safety of adalimumab in Crohn's disease during pregnancy: Case report and review of the literature

Inflammatory Bowel Diseases

Volumn 16, Issue 10, 2010, Pages 1634-1636

  Jürgens, Matthias ^a,b   Brand, Stephan ^a,b   Filik, Levent ^a,b   Hübener, Christoph ^a,b   Hasbargen, Uwe ^a,b   Beigel, Florian ^a,b   Tillack, Cornelia ^a,b   Göke, Burkhard ^a,b   Ochsenkühn, Thomas ^a,b   Seiderer, Julia ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Ankara Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ANUS ATRESIA; AORTA ARCH SYNDROME; CASE REPORT; CONCEPTION; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROHN DISEASE; DELIVERY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HOSPITAL ADMISSION; HUMAN; KIDNEY MALFORMATION; LETTER; MAINTENANCE THERAPY; PREGNANCY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TRACHEOESOPHAGEAL ANOMALY; ULCERATIVE COLITIS; VERTEBRA MALFORMATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649232947     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21198     Document Type: Letter

References (7)

1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
2. Podolsky DK,. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-429.
3. Schnitzler F, Fidder HH, Ferrante M, et al. Intentional treatment with infliximab during pregnancy in women with inflammatory bowel disease. Gastroenterology. 2007; 132: A144.
4. Angelucci E, Cocco A, Viscido A, et al. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm Bowel Dis. 2008; 14: 435-436.
5. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009; 36: 635-641.
6. Giroir BP, Peppel K, Silva M, et al. The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw. 1992; 3: 533-538.
7. Simister NE,. Placental transport of immunoglobulin G. Vaccine. 2003; 21: 3365-3369.